ArticleDigestive diseases and sciences2026
Comprehensive Benefit Evaluation and Clinical Decision-Making After 4-week Cinitapride Treatment on Functional Dyspepsia: A Multicenter, Prospective Designed, Real-World Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFunctional dyspepsia (FD) is a functional gastrointestinal disorder diagnosed by symptom-based criteria. This study aimed to evaluate the efficacy of 8-week cinitapride treatment in patients with FD and to explore the appropriate clinical decision after 4 weeks of therapy.
methodsThis real-world, multicenter, prospective study enrolled 1,530 FD patients meeting Rome IV criteria from nearly 100 gastroenterology centers in China between September 2020 and January 2021. A total of 1,313 patients completed the 8-week follow-up. The primary endpoint was the effective remission rate (ERR) of cinitapride from weeks 4 to 8. ANCOVA and Cox regression analyses were performed to adjust for baseline characteristics and identify efficacy predictors.
resultsAfter covariate adjustment, patients continuing cinitapride during weeks 4-8 showed significantly higher remission rates than nonusers (β = 14.52, t = 2.016, p = 0.044). Cox regression identified younger age, lower BMI, higher education, nonpostprandial distress syndrome (non-PDS) subtype, and both maintenance (HR = 9.18, p < 0.001) and on-demand (HR = 8.54, p < 0.001) regimens as independent predictors of response. In patients under 60 years, the PDS subtype was associated with greater efficacy (HR = 2.00, p = 0.019). Treatment effects were consistent across age groups.
conclusionEight weeks of cinitapride treatment significantly improved symptom remission in patients with FD, particularly those under 60 years with the PDS subtype. Response after 4 weeks of therapy may guide individualized decisions on whether to continue or discontinue treatment, with on-demand use showing favorable efficacy and reduced exposure. The Name of the Trial Registry: Clinical efficacy and safety of prokinetic agents as maintenance therapy for functional dyspepsia (FD): a real-world study. The Registration Number of the Trial: https://www. CLINICALTRIALS: gov/ (ChiCTR2100042166).
Indexed as
Identifiers
41329381What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.